Milwaukee, WI4 Active Studies

Rheumatoid Arthritis Clinical Trials in Milwaukee, WI

Find 4 actively recruiting rheumatoid arthritis clinical trials in Milwaukee, WI. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
1,445
Enrolling

Recruiting Rheumatoid Arthritis Studies in Milwaukee

RecruitingMilwaukee, WINCT05437575

Prehospital Analgesia INtervention Trial (PAIN)

The Prehospital Analgesia INtervention trial (PAIN) is a proposed 4 year (3-year enrollment) multicenter, prehospital, randomized, double-blind, clinical trial that will enroll approximately 994 patie...

994 participants
Jason Sperry
View Study Details
RecruitingMilwaukee, WINCT05707377

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with ...

282 participants
BeiGene
View Study Details
RecruitingMilwaukee, WINCT05776069

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand...

116 participants
Vega Therapeutics, Inc
View Study Details
RecruitingMilwaukee, WINCT05045950

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal r...

53 participants
Medical College of Wisconsin
View Study Details

About Rheumatoid Arthritis Clinical Trials in Milwaukee

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.

There are currently 4 rheumatoid arthritis clinical trials recruiting participants in Milwaukee, WI. These studies are seeking a combined 1,445 participants. Research is being sponsored by Jason Sperry, BeiGene, Vega Therapeutics, Inc and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Rheumatoid Arthritis Clinical Trials in Milwaukee — FAQ

Are there rheumatoid arthritis clinical trials in Milwaukee?

Yes, there are 4 rheumatoid arthritis clinical trials currently recruiting in Milwaukee, WI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Milwaukee?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Milwaukee research site will contact you about next steps.

Are clinical trials in Milwaukee free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Milwaukee studies also compensate for your time and travel.

What rheumatoid arthritis treatments are being tested?

The 4 active trials in Milwaukee are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.

Data updated March 2, 2026 from ClinicalTrials.gov